IL10 and esophageal squamous cell carcinoma: In another study conducted by Samiei et al.; they compared CD3+CD8+ T cells from 34 patients who have ESCC (12 recently diagnosed: ND, 24 under-treated: UT) to CD3+CD8+ T cells from 34 matched healthy donors to ascertain the diagnostic and/or prognostic utilities of IL-10, IFN-γ, and TGF-β, as well as IL-17a producing CD8+ CD3+ T cells (after 160 weeks of follow-up) (Wang D. et al., 2015).